// App-Quantinova.ai

: Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Researchers

Presenter

  • Stephen E Kurtz

Principal Investigators

  • Christopher A. Eide

  • Narain P. Dubey

  • Andy Kaempf

  • Shannon K. McWeeney

  • Cristina E. Tognon

  • Motomi Mori

  • Brian J. Druker

  • Jeffrey W. Tyner

  • Anupriya Agarwal

Medical Centers

  • Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR

  • Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR

  • Howard Hughes Medical Institute, Portland, OR

  • Knight Cancer Institute, Biostatistics Shared Resource, Oregon Health & Science University, Portland, OR

  • Knight Cancer Institute, Division of Bioinformatics and Computational Biology, Oregon Health and Science University, Portland, OR

  • School of Public Health, Portland State University/Oregon Health & Science University, Portland, OR

  • Division of Surgical Oncology, Oregon Health & Science University, Portland, OR

  • Department of Cell & Developmental Biology, Oregon Health & Science University, Portland, OR

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Myeloid neoplasms

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

Biomarkers

  • Nucleophosmin 1

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Doramapimod

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved